Mizuho Analyst Calls Cadence and Synopsys Dip a Buying Opportunity After Kimi K3 AI Chip Shock
Mizuho sees agentic AI tripling the EDA market and maintains Outperform ratings.
Already have an account? Sign in.
Mizuho sees agentic AI tripling the EDA market and maintains Outperform ratings.
The FDA approved Scholar Rock’s Isembyld, the first SMA therapy aimed at muscle wasting in patients already on nerve-targeted treatment.
The Phase III SERENA-4 trial did not meet its primary PFS endpoint in untreated advanced ER-positive, HER2-negative breast cancer, despite a numerical benefit.
Citi added a 90-day upside view on AppLovin with a $600 target, calling Q3 concerns misguided.